PVI
SYRE icon

Pura Vida Investments’s Spyre Therapeutics SYRE Stock Holding History

Pura Vida Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,948
Closed -$472K – 164
2022
Q4 		$472K Buy
+41,948
New +$754K 0.02% 165

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Pura Vida Investments's SYRE Position: Q1 2023 in Review

Pura Vida Investments sold out of Spyre Therapeutics (SYRE) in Q1 2023, closing a stake of 41,948 shares — an estimated $472K sold.

Pura Vida Investments first reported a position in SYRE in Q4 2022 and held it in 1 quarter. The position peaked at $472K in Q4 2022. 44 funds tracked by Wall St. Rank hold SYRE as of Q1 2023.

  • Pura Vida Investments reported no remaining Spyre Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 41,948 Spyre Therapeutics shares in Q1 2023, an estimated $472K.
  • Pura Vida Investments first reported a position in Spyre Therapeutics in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Spyre Therapeutics position peaked at $472K in Q4 2022.
  • 44 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.